blablo101-shutterstock-com-eu-law-
Blablo101 / Shutterstock.com
14 July 2016PharmaSimon Spink and Adrian Chew

Varying approaches: granting SPCs in Europe

Supplementary protection certificates (SPCs) are a hugely important intellectual property right for the pharmaceutical industry as they can extend patent protection for a particular pharmaceutical product for up to five additional years.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
14 July 2026   An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.
Pharma
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.